Update on BRS

Session comprising selected EuroPCR 2016 late-breaking trial submissions

Presentations available when logged in:

  • Two-year clinical, angiographic and serial OCT follow-up after implantation of everolimus-eluting BRS and everolimus-eluting metallic stent: insigh...
  • Six-year follow-up of the first-in-man use of a polylactide everolimus-eluting BRS for the treatment of coronary stenosis: an assessment of FFR by...
  • France ABSORB registry: in-hospital and one-month results in 2,000 patients